Rapid decrease of 7-valent conjugate vaccine coverage for invasive pneumococcal diseases in pediatric patients in Japan

Microb Drug Resist. 2013 Aug;19(4):308-15. doi: 10.1089/mdr.2012.0180. Epub 2013 Mar 12.

Abstract

In Japan, the heptavalent pneumococcal conjugate vaccine (PCV7) has been introduced on a voluntary basis since February 2010, and official financial support for children under 5 years started in November 2010. The impact of PCV7 on invasive pneumococcal diseases (IPD) in children is unknown. There are 340 medical institutions that actively participated in our surveillance project throughout Japan. We collected 252 strains from patients with IPD in 2006 (pre-PCV7), 280 strains in 2010 (under 10% immunization achieved), and 128 strains in 2011 (50% to 60% immunization). Serotypes and penicillin-resistance genotypes (g) were compared between these years. Multilocus sequence typing was also carried out on these strains. Due to the official promotion, IPD significantly decreased in 2011 (p<0.001). In particular, meningitis and sepsis caused by vaccine type (VT) strains declined (p=0.033, p<0.001). In less than 2 years, among nonvaccine types (NVT), 15A and 22F increased in 2011 (p=0.015, p=0.015). Coverage by PCV7 decreased from 71.8% in 2006 to 51.6% in 2011. Sequence-type diversities accompanied by evolution to gPRSP occurred in both VT and NVT strains. Reduction of IPD caused by VT strains was accomplished, but a rapid increase of NVT raises concern about a future decrease in the efficacy of PCV7.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Child
  • Child, Preschool
  • DNA, Bacterial / classification
  • DNA, Bacterial / genetics*
  • DNA, Bacterial / immunology
  • Epidemiological Monitoring
  • Female
  • Heptavalent Pneumococcal Conjugate Vaccine
  • Humans
  • Infant
  • Japan / epidemiology
  • Male
  • Meningitis, Bacterial / epidemiology
  • Meningitis, Bacterial / immunology
  • Meningitis, Bacterial / microbiology
  • Meningitis, Bacterial / prevention & control*
  • Microbial Sensitivity Tests
  • Multilocus Sequence Typing
  • Pneumococcal Infections / epidemiology
  • Pneumococcal Infections / immunology
  • Pneumococcal Infections / microbiology
  • Pneumococcal Infections / prevention & control*
  • Pneumococcal Vaccines / administration & dosage*
  • Pneumococcal Vaccines / immunology
  • Sepsis / epidemiology
  • Sepsis / immunology
  • Sepsis / microbiology
  • Sepsis / prevention & control*
  • Serotyping
  • Streptococcus pneumoniae / classification
  • Streptococcus pneumoniae / drug effects
  • Streptococcus pneumoniae / genetics
  • Streptococcus pneumoniae / immunology*
  • Vaccination*

Substances

  • DNA, Bacterial
  • Heptavalent Pneumococcal Conjugate Vaccine
  • Pneumococcal Vaccines